Author Archives: UroGen

Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study

Urology. 2016 Oct 5. pii: S0090-4295(16)30689-6. doi: 0.1016/j.urology.2016.09.039. [Epub ahead of print] Donin NM1, Duarte S2, Lenis AT3, Caliliw R3, Torres C2, Smithson A2, Strauss-Ayali D4, Agmon-Gerstein Y4, Malchi N4, Said J5, Raman SS6, Holden S3, Pantuck A7, Belldegrun AS7, … Continue reading

Posted in Publications | Leave a comment

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer

Journal of Urologic Oncology, 2016 Nicholas M. Donin, Karim Chamie, Andrew T. Lenis, Allan J. Pantuck, Madhu Reddy, Dana Kivlin, Johanna Holldack, Rafaella Pozzi, and others Highlights •TMX-101 0.4% is a novel intravesical formulation of imiquimod, a toll-like receptor agonist. … Continue reading

Posted in Publications | Leave a comment

Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: A double-blind randomized pilot study.

Scand J Urol. 2016 Jun;50(3):200-5. Krhut J1, Navratilova M2, Sykora R1, Jurakova M2, Gärtner M2, Mika D1, Pavliska L3, Zvara P4. 1 Department of Urology , University Hospital , Ostrava , Czech Republic 2 Department of Obstetrics and Gynecology , University Hospital , … Continue reading

Posted in Publications | Leave a comment

A Phase 2 Study of Vesimune®, intravesical imiquimod, for the Treatment of Carcinoma in Situ Bladder Cancer

AUA poster presentation, Saturday, May 7, 2016 10:30 AM-11:30 AM A Phase 2 Study of Vesimune®, intravesical imiquimod, for the Treatment of Carcinoma in Situ Bladder Cancer Nicholas Donin*, Karim Chamie, Los Angeles, CA, Madhu Reddy, Philadelpia, PA, Dana Kivlin, … Continue reading

Posted in Publications | Leave a comment

The Chemoablative Effect of VesiGel® Instillation in Patients with NMIBC – Preliminary Results

AUA poster presentation, Saturday, May 7, 2016 8:00 AM-10:00 AM The Chemoablative Effect of VesiGel® Instillation in Patients with NMIBC – Preliminary Results Boris Friedman*, Yoram Dekel, Haifa, Israel, Andrea Tubaro, Rome, Italy, Ami Sidi, Benjamin Shalva, Holon, Israel, Jack Baniel, … Continue reading

Posted in Publications | Leave a comment

Preclinical trial of serial MitoGel® instillations into the pelvicalyceal system of the Yorkshire swine

AUA poster presentation, Saturday, May 7, 2016 8:00 AM-10:00 AM Preclinical trial of serial MitoGel® instillations into the pelvicalyceal system of the Yorkshire swine Nicholas Donin*, Sandra Duarte, Los Angeles, CA, Dalit Strauss-Ayali, Yael Agmon-Gerstein, Nadav Malchi, Ra’anana, Israel, Allan … Continue reading

Posted in Publications | Leave a comment

UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting

New York, NY and Ra’anana, Israel, May 5th, 2016: UroGen Pharma, a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today that the Company has been selected to present two oral/podium … Continue reading

Posted in News | Leave a comment

UroGen Pharma Strengthens Board of Directors and Senior Management Team

Appoints Stuart Holden, M.D., to its Board of Directors and Mark Schoenberg, M.D., as Medical Director New York, NY and Ra’anana, Israel, February 8, 2016: UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with … Continue reading

Posted in News | Leave a comment

UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset

New York, NY and Ra’anana, Israel, January 13, 2016: UroGen Pharma, Ltd. (formerly known as TheraCoat), a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today the appointment of two key … Continue reading

Posted in News | Leave a comment

AUA 2016, San Diego

AUA 2016, May 6-10. UroGen Pharma will exhibit at the American Urology Association Annual Meeting and meet investigators and companies interested in collaboration.

Posted in Events | Leave a comment